Pfizer Inc., New York, New York, was awarded a $1,959,999,848 modification (P00005) to contract W58P05-22-C-0001 for the oral therapeutic Paxlovid. Work will be performed in New York, New York, with an estimated completion date of Dec. 31, 2028. Fiscal 2021 Coronavirus Preparedness Response and Relief Supplemental Appropriations Act funds in the amount of $1,959,999,848 were obligated at the time of the award. U.S. Army Contracting Command, New Jersey, is the contracting activity.
